GlassScriptPhysician profile
Alexander E Schuetz
NPI 1962400291
$11,074.52
in general payments reported to CMS, 2019-2025
56 companies · $157 in 2025
The $157 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $1,989 · 2021: $2,045 · 2022: $2,027 · 2023: $1,980 · 2024: $1,375 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,512.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,221.51 | 2019-2024 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $1,205.16 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,159.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,085.44 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,048.50 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $706.01 | 2019-2024 | Evenity, Prolia, Otezla |
| Supernus Pharmaceuticals, INC. | $550.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $440.45 | 2019-2024 | |
| Atricure, INC. | $394.06 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.31 | 2019-2024 | Jardiance |
| Abbott Laboratories | $306.68 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Pharmaceuticals, INC | $222.22 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $215.55 | 2019-2023 | Eliquis |
| Lilly USA, LLC | $157.55 | 2019-2023 | Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $145.11 | 2019-2021 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Schuetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.